From: Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)
Age-group | % Seroprotection | CI 95% |
---|---|---|
3-4 years | 2.0% | [ 0.1%,5.8%] |
5-6 years | 4.0% | [ 0.7%,8.2%] |
7-8 years | 5.6% | [ 2.1%,9.8%] |
9-11 years | 6.6% | [ 2.9%,11.0%] |
12-13 years | 8.2% | [ 4.0%,12.6%] |
14-16 years | 9.6% | [ 5.2%,14.3%] |
17-19 years | 11.0% | [ 6.4%,15.6%] |
20-21 years | 12.3% | [ 7.8%,16.8%] |
22-29 years | 13.7% | [ 9.4%,18.0%] |
30-39 years | 15.2% | [ 11.4%,19.2%] |
40-49 years | 16.2% | [ 12.3%,20.5%] |
50-59 years | 18.1% | [ 13.5%,23.3%] |
≥ 60 years | 26.6% | [ 20.2%,34.1%] |